rais forecast reflect merck deal
action rais estim eisai increas target price
maintain neutral rate
invest overview revis forecast reflect tie-up
merck announc march specif includ one-tim
payment merck estim accompani
mileston payment increas sale eisai anti-cancer drug lenmiva
estim eisai stand receiv
cash merck term deal aim
joint develop lenmiva merck immunotherapy/anticanc
drug keytruda combin therapi could increas sale potenti
current regard deal major benefit eisai
new forecast premis eisai secur averag op
near-term benchmark share surg news
merck collabor think upsid look limit
catalysts/risk await final analysi around next august phase
result alzheim drug incom merck
major swing factor np pose risk earn share price
valuat becom less demand view continu see
strong possibl substanti share price movement depend
success failur alzheim drug develop
valuat target price base ep
previous forward price-to-earnings
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price upsid rate neutral target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
background share price rise lower valuat
announc tie-up merck oncolog posit surpris assum
success eisai receiv total one-off payment
reimburs spend mileston
payment put maximum potenti valu deal
return gross profit drug global sale split equal two
compani see deal extrem advantag eisai rais op
ep estim factor mileston payment revis target
net incom attribut
owner parent compani
cash equival
compani mention price
